Imaging the glutamatergic system in vivo - Relevance to schizophrenia

European Journal of Nuclear Medicine

Volumn 27, Issue 11, 2000, Pages 1723-1731

  Bressan, Rodrigo A ^a   Pilowsky, Lyn S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Glutamate; Ligands; NMDA; Positron emission tomography; Schizophrenia; Single photon emission tomography

Indexed keywords

AMPA RECEPTOR; CARBON 11; CNS 1261; CYCLOSERINE; DIZOCILPINE; DOPAMINE; DOPAMINE RECEPTOR; FLUORINE 18; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; GUANIDINE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; IODINE 123; IODINE 125; KAINIC ACID RECEPTOR; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NAPHTHYL IODOPHENYL METHYLGUANIDINE; NEUROLEPTIC AGENT; PHENCYCLIDINE; PIPERIDINE DERIVATIVE; RADIOLIGAND; SERINE; THIENYL CYCLOHEXYL PIPERIDINE; UNCLASSIFIED DRUG;

DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; HYPOTHESIS; IN VIVO STUDY; ISOTOPE TRACING; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHOTON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; RAT; REVIEW; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

BRAIN CHEMISTRY; HUMANS; KETAMINE; MEMANTINE; RECEPTORS, AMPA; RECEPTORS, DOPAMINE D2; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0033754407     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590000372     Document Type: Review

References (70)

1. The economic impact of schizophrenia
2. Meta-analysis of regional brain volumes in schizophrenia
3. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia
4. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
5. The neuropathology of schizophrenia - A critical review of the data and their interpretation
6. Functional brain imaging: Twenty-first century phrenology or psychobiological advance of the millennium
7. In vivo neuropharmacology of schizophrenia
8. Increased dopaminergic transmission in schizophrenia: Relationship to illness phases
9. The regulation of forebrain dopamine transmission: Relevance to the pathology and psychopathology of schizophrenia
10. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
11. Excitatory amino acid neurotransmission
12. Glutamate receptor expression in schizophrenic brain
13. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects
14. Clozapine, single photon emission tomography, and the D2 dopamine receptor
15. 123I-IBZM SPET study
16. Asymmetrical loss of glutamate receptor subtype in the left hippocampus in schizophrenia
17. 3H]MK-801 binding sites in post-mortem brain regions of schizophrenic patients
18. Mice with reduced NMDA receptor expression display behaviours related to schizophrenia
19. Study of a new schizophrenomimetic drug, Sernyl
20. Delaney Sub-anesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans
21. Effects of N-methyl-D-aspartate receptor antagonist ketamine on striatal dopamine release in schizophrenia
22. Effect of phencyclidine in chronic schizophrenics
23. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia
24. Recent advances in the phencyclidine model of schizophrenia
25. Glutamate in schizophrenia: Clinical and research implications
26. Electrical stimulation of the medial prefrontal cortex increases dopamine release in the striatum
27. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine
28. Effects of NMDA antagonism on striatal dopamine release in healthy subjects: Application of a novel PET approach
29. 11C]-raclopride in normal human subjects
30. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort
31. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method
32. Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats
33. Ketamine modulation of amphetamine-induced striatal dopamine release in healthy volunteers
34. The neuropharmacology of NMDA receptors in schizophrenia - A neuroimaging perspective
35. D-Serine added to antipsychotics for the treatment of schizophrenia
36. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
37. Efficacy of high-dose glycine in the treatment of enduring negative symptoms
38. Receptor specific radiopharmaceuticals
39. 18F-MEM): A potential radioligand for mapping the NMDA-receptor complex
40. 3H]TCP binding to the activated NMDA-receptor-gated ion channel in rat brain
41. Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore
42. Positron-emitting radioligands for studies in vivo probes for human psychopharmacology
43. Excitatory amino acid receptors in the brain: Membrane binding and receptor autoradiographic approaches
44. 3H]MK-801 binding and the mRNA for the NMDAR1 subunit of the NMDA receptor are differentially distributed in human and rat forebrain
45. NMDA receptor channels: Labelling of MK-801 with iodine-125 and fluorine-18
46. 18F]5-(beta-fluoroethyl)-10,11-dihydro-5H-dibenzoclycloheptene-5,10-imine
47. 11C]MK801]
48. Synthesis and receptor binding studies of (+/-)1-iodo-MK-801
49. 123I]Iodc-MK-801: Synthesis and characterization of binding to the N-methyl-D-aspartate receptor complex
50. 123Iodo-MK-801: A SPECT agent for imaging the pattern and extent of glutamate (NMDA) receptor activation in Alzheimer's disease
51. First SPET images of glutamate (NMDA) receptor activation in vivo in cerebral ischaemia
52. 18F]methyl-MK-801, a potential NMDA receptor complex radioligand
53. Synthesis of a C-11-labelled derivate of the NMDA receptor antagonist MK-801
54. 11C]cyano-dizocilpine
55. Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as NMDA receptor ion channel blockers
56. Imaging of NMDA receptor activation in acute Stroke
57. In vivo study of NMDA-sensitive glutamate receptor by fluorothienylcyclohexylpiperidine, a possible ligand for positron emission tomography
58. 18F]fluoroethyl)-2-thienyl]-cyclohexyl)piperidine as a potential in vivo radioligand for the NMDA receptor-channel complex
59. 18F-labelled thienylcyclohexylpiperidine (TCP) analogues as radioligands for the NMDA receptor-channel complex
60. 11C]-ketamine in the rhesus monkey studied by positron emission tomography
61. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons
62. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers
63. NMDA-receptor activity with (S)-[N-methyl-11C]-ketamine and positron emission tomography in patients with medial temporal lobe epilepsy
64. 18F]fluoromethyl-5-methyl-adamantane. A potential ligand for mapping the NMDA-receptor complex
65. Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor
66. 11C]L-703, 717 as a radioligand for the glycine site of the NMDA receptor
67. Synthesis, radiolabelling and biological characterization of (D)-7-iodo-N-(1-phosphonoethyl)-5-aminome-thylquinoxaline-2,3-dione, a glycine-binding site antagonist of NMDA receptors
68. Excitatory amino acid receptors and their role in epilepsy and cerebral ischemia
69. Neurotransmitter receptors